CAR-T Therapies: Stakeholders Urge Rethinking Of Postmarketing Requirements And REMS

 
• By Sue Sutter
  
Reflect, rethink, revise
CAR-T therapy postmarketing safety requirements could be ripe for re-examination. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies